Value
—- Trailing PER (last 12 months)
- —
- EPS zero or negative; no PER
- CautionEPS zero or negative
Not applicable
BIAF
bioAffinity Technologies, Inc.
BIAF
bioAffinity Technologies, Inc.
$ 3.9
-
Not applicable
Shown as separate facts (no combined rating)As of 2026-10-12
Insufficient data
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
| Asset | Price | Div. Yield |
|---|